(Corrects premium to 28.3 percent from 7.68 percent in paragraph 2)
Aug 20 (Reuters) - China Biologic Products Holdings Inc on Monday received a $3.9 billion all-cash offer from a consortium that included company’s former chief executive, GL Capital Group, Bank of China Group Investment Limited and CDH Investments.
The consortium said it offered $118 per share, which represents a premium of 28.3 percent to China Biologic’s Friday closing price.
China Biologic makes and sells plasma products such as human immunoglobin to prevent diseases such as measles and hepatitis.
In June, Chinese investment firm CITIC Capital Holdings had made a cash offer to buy the company for $110 per share, valuing at $3.65 billion.
Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur